News & Events
Nov 10, 2025 1:11:48 PM / by Orchestra BioMed posted in Regulatory
This week marks a major milestone for Orchestra BioMed that has potentially significant implications for the commercial potential of AVIM therapy that OBIO is pursuing with its strategic partner, Medtronic.
Nov 10, 2025 1:10:11 PM / by Orchestra BioMed posted in Regulatory
Yesterday, we shared exciting news that Orchestra BioMed has been awarded FDA Breakthrough Device Designation for our novel AVIM therapy. If you missed the announcement, here’s a quick overview of this significant clinical and regulatory milestone:
Nov 10, 2025 12:09:32 PM / by Orchestra BioMed posted in Regulatory
© 2025 Orchestra BioMed Inc. Virtue®, BackBeat CNT™ FreeHold Duo®, FreeHold Trio® and Orchestra BioMed™ are trademarks of Orchestra BioMed.
All other trademarks are trademarks of their respective owners.
SM-0020 Rev 01
